Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tripterygium wilfordii multiglycoside (TWM) is a purified botanical extract derived from the root of the *Tripterygium wilfordii* Hook. f. vine, a plant long used in traditional Chinese medicine. It is a regulated pharmaceutical product in China, primarily utilized for its potent immunosuppressive and anti-inflammatory properties. TWM contains a complex mixture of diterpenoids (such as triptolide) and triterpenoids (such as celastrol) that modulate immune responses by inhibiting the production of pro-inflammatory cytokines and suppressing the activity of T-lymphocytes. It is widely prescribed for autoimmune and inflammatory conditions, including rheumatoid arthritis, systemic lupus erythematosus, and various forms of nephritis. Recent clinical investigations have expanded its potential use to degenerative conditions such as hand osteoarthritis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tripterygium wilfordii multiglycoside.